| Literature DB >> 19648939 |
Eamonn S Molloy1, Leonard H Calabrese.
Abstract
In April 2009, efalizumab was withdrawn from the market for the treatment of psoriasis after reports emerged of an association between long-term therapy and the development of progressive multifocal leukoencephalopathy (PML). This event highlights an urgent need for greater awareness and research into the screening, diagnosis and treatment of this potentially fatal disease in patients undergoing immunosuppressive therapy for chronic inflammatory disorders.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19648939 DOI： 10.1038/nrrheum.2009.142
Source DB: PubMed Journal: Nat Rev Rheumatol ISSN： 1759-4790 Impact factor: 20.543